INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

PLXProtalix BioTherapeutics, Inc.

CIK 0001006281

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 0
Max Insider Score9
Connections6with evidence

PLX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
EC
Elze ChristianDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
17.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Naos YaronSr. VP & COO · Sep 4, 2026
  • ← Insider ofevidence
    Elze ChristianDirector · Sep 4, 2026
  • ← Insider ofevidence
    Ben Zvi ShmuelDirector · Sep 4, 2026
9
EC
Elze ChristianDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A
—
8,500 sh
Sep 3, 2026
Sep 4, 2026
traded Sep 3, 2026
+1d
SEC FORM 4

Evidence

9
BS
Ben Zvi ShmuelDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
17.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
BS
Ben Zvi ShmuelDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
8,500 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
FE
Forster EliotDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
17.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
FE
Forster EliotDirector
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
8,500 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
BD
Bashan DrorDirector, PRESIDENT AND CEO
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
320.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
BD
Bashan DrorDirector, PRESIDENT AND CEO
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
160.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
NY
Naos YaronSr. VP & COO
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
112.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
NY
Naos YaronSr. VP & COO
PLXProtalix BioTherapeutics, Inc.
Grant or award
A—
56.0K sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

← Insider ofevidence
Forster Eliot
Director · Sep 4, 2026
  • ← Insider ofevidence
    Bashan DrorDirector, PRESIDENT AND CEO · Sep 4, 2026